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Abstract
Background: Evidence that selenium affects the risk of type-2 diabetes is conflicting, with observational studies and a few
randomized trials showing both lower and higher risk linked to the level of selenium intake and status. We investigated the
effect of selenium supplementation on the risk of type-2 diabetes in a population of relatively low selenium status as part of
the UK PRECISE (PREvention of Cancer by Intervention with SElenium) pilot study. Plasma adiponectin concentration, a
recognised independent predictor of type-2 diabetes risk and known to be correlated with circulating selenoprotein P, was
the biomarker chosen.
Methods: In a randomized, double-blind, placebo-controlled trial, five hundred and one elderly volunteers were randomly
assigned to a six-month intervention with 100, 200 or 300 mg selenium/d as high-selenium or placebo yeast. Adiponectin
concentration was measured by ELISA at baseline and after six months of treatment in 473 participants with one or both
plasma samples available.
Results: Mean (SD) plasma selenium concentration was 88.5 ng/g (19.1) at baseline and increased significantly in the
selenium-treatment groups. In baseline cross-sectional analyses, the fully adjusted geometric mean of plasma adiponectin
was 14% lower (95% CI, 0–27%) in the highest than in the lowest quartile of plasma selenium (P for linear trend = 0.04). In
analyses across randomized groups, however, selenium supplementation had no effect on adiponectin levels after six
months of treatment (P = 0.96).
Conclusions: These findings are reassuring as they did not show a diabetogenic effect of a six-month supplementation with
selenium in this sample of elderly individuals of relatively low selenium status.
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Introduction
The relationship between selenium (Se) and type-2 diabetes is a
conundrum. That a relationship should exist is unsurprising given
the clear link found between diabetes or insulin resistance and a
number of selenoproteins in both human and animal studies [1–7].
Results from epidemiological studies on Se and type-2 diabetes are
conflicting. Higher serum Se concentration was associated with a
higher prevalence of diabetes in several cross-sectional studies [8–
11]. However, longitudinal studies have not supported a causal
role for Se in type-2 diabetes [10,12]; indeed, high plasma Se was
associated with a decreased risk of onset of hyperglycemia over a
nine-year follow-up period among male participants in the
prospective French EVA study [12].
Results of randomised trials have also been inconclusive. The
Nutritional Prevention of Cancer (NPC) trial, carried out in the
eastern US, showed a significantly increased risk of type-2 diabetes
in those supplemented with Se (200 mg/day as Se-yeast) over an
average period of 7.7 years [13]. The increased risk was driven by
those in the highest tertile of plasma Se at baseline. By contrast, in
the large Selenium and Vitamin E Cancer Prevention Trial
(SELECT), there was a small non-significant increase in the
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number of cases of adult-onset diabetes in subjects supplemented
with Se alone (200 mg/day as selenomethionine) [14] that
diminished further on follow-up for an additional 18 months [15].
To advance our understanding of the effect of Se on the risk of
type-2 diabetes, we used stored plasma samples from the UK
PRECISE (PREvention of Cancer by Intervention with SElenium)
pilot study to test the effect of Se supplementation on plasma
adiponectin, a strong independent predictor of type-2 diabetes risk
[16–20]. Adiponectin sensitizes skeletal muscle and liver to the
action of insulin and stimulates glucose uptake via the cellular fuel
sensor, AMP-activated protein kinase (AMPK) [21;22]. Adipo-
nectin has been linked to Se or selenoproteins in a number of
ways, though as with the epidemiology, the relationship is not
straightforward: (i) circulating selenoprotein P was negatively
associated with circulating adiponectin in patients with type-2
diabetes [5]; (ii) patients with markedly reduced expression of
selenoproteins due to a rare defect in the SECISBP2 gene had
elevated blood adiponectin and enhanced insulin signalling [23];
(iii) selenoprotein P knock-out mice had significantly higher blood
adiponectin levels than wild-type mice [5]; (iv) Se supplementation
of macrophages increases the production of 15-deoxy-Delta12,14-
prostaglanin J2 (15d-PGJ2), an activator of peroxisome prolif-
erator-activated nuclear receptor-c (PPAR-c) [24]; this is relevant
because PPAR-c agonists have been shown to increase the
expression and protein levels of adiponectin [25,26]; (v) knock-
down of selenoprotein P in adipocytes markedly lowered the
expression of both adiponectin and PPAR-c [27]. Furthermore,
both Se/selenoprotein P and adiponectin are associated with
raised HDL cholesterol [20,28,29] and reduced inflammation
[20,28,30], and both can affect AMPK, though in opposite
directions [4,22]. Most importantly for our study, adiponectin is a
useful biomarker of type-2 diabetes risk in non-fasted plasma
samples, which ours are, as diurnal variability is minor and there is
no noticeable effect of food intake [16,31,32].
In PRECISE, 501 elderly volunteers were randomly assigned to
a six-month intervention with 100, 200 or 300 mg Se/d as high-Se
or placebo yeast [29,33,34]. PRECISE participants come from a
population of relatively low Se status where antioxidant seleno-
proteins such as glutathione peroxidase and selenoprotein P are
unlikely to be optimised at baseline. We hypothesised that the
100 mg dose might increase plasma adiponectin concentration
(indicative of a reduced risk of type-2 diabetes) by optimising
selenoprotein activity, whereas the much higher 300 mg dose
might potentially have an adverse effect.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
The study had approval from UK Local Research Ethics
Committees [South Tees (ref: 99/69), Worcestershire Health
Authority (ref: LREC 74/99), Norwich District (ref: LREC 99/
141), Great Yarmouth and Waveney (under reciprocal arrange-
ments with Norwich District LREC)] and participants provided
written informed consent.
Design and Study Population
The UK pilot study for the planned international PRECISE
(Prevention of Cancer by Intervention with Selenium) trial was
designed to assess the viability of conducting the trial in the UK.
The UK PRECISE pilot (ISRCTN 25193534) was a double-blind,
placebo-controlled, four-arm parallel-group study, stratified by age
and sex [29,33,34]. The target accrual (501 subjects in 12 months)
was chosen to give sufficient subjects to draw reasonable inferences
about recruitment, compliance and loss to follow-up.
Volunteers were recruited from four general practices (study
centers) in different parts of the country (see Table 1) affiliated
with the Medical Research Council (MRC) General Practice
Research Framework. Between June 2000 and July 2001, research
nurses recruited similar numbers of men and women from each of
three age groups: 60–64, 65–69 and 70–74 years. Exclusion
criteria were: i) a Southwest Oncology Group performance status
score .1 (i.e. incapable of carrying out light housework or office
work); ii) active liver or kidney disease; iii) prior diagnosis of cancer
(excluding non-melanoma skin cancer); iv) diagnosed HIV
infection; v) on immunosuppressive therapy; vi) diminished mental
capacity; vii) taking $50 mg/day of Se supplements in the previous
six months (by patient report).
Randomization and Interventions
Computer-generated random permuted blocks, stratified by
study center, gender and age group were used to generate the
randomization list at the Clinical Trials and Statistics Unit,
Institute of Cancer Research, Sutton Surrey, UK. Following a
four-week placebo run-in, 501 volunteers were randomly assigned
(allocation ratio 1:1:1:1) to one of four treatment regimens:
placebo, 100, 200 or 300 mg of Se per day for a minimum of six
months. The intervention agent was high-Se yeast, SelenoPreci-
seTM (Pharma Nord, Vejle, Denmark), or an identical placebo
yeast (comprising 250 mg yeast placebo, 80 mg cellulose, 65 mg
dicalcium phosphate, and #5 mg of other inactive ingredients).
Participants, research nurses, other study center personnel,
investigators and those who analyzed the data were blinded to
treatment.
Data Collection and Follow-up
Demographic data, medical history, and other health-related
information, including medication and supplement use, were
collected at baseline. Of 501 randomised participants, 34 withdrew
from treatment (Figure 1). However, there was no statistically
significant difference in numbers of participants withdrawing
across treatment groups (P from Pearson’s chi-squared test
= 0.31).
Participants provided a non-fasting blood sample at both
baseline and six months. Heparinised plasma was prepared and
frozen at the study centers. Plasma samples were transferred to the
University of Surrey on dry ice where they were stored at 280uC.
At the six-month follow-up appointment, questionnaires were used
to see if there had been any new symptoms or illnesses since
randomization and whether use of medication and supplements
had changed. Compliance with randomised treatment was
determined by pill count. Participants were considered compliant
if they took at least 80% of their allocated tablets. In addition, each
participant’s plasma Se was compared with the mean of the group
to detect non-compliant participants or ‘‘drop-ins’’. Reasons for
participant withdrawal were noted.
The last planned six-month follow-up visit (with blood draw)
was in January 2002. However, volunteers, who were to have been
the first cohort of the main PRECISE trial, continued treatment
and six-month follow-up visits until mid-2003 when it became
clear that the international study was not going to be funded.
Selenium Measurement
Lithium-heparin plasma was analysed for Se at Central Science
Laboratory, Sand Hutton, UK, by hydride-generation Inductive-
Selenium Supplementation and Adiponectin
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ly-Coupled-Plasma Mass Spectrometry as previously described.
Quality control procedures accredited under the UK Accredita-
tion Scheme were followed. Accuracy was assured by good
performance on the analysis of certified reference materials [34].
Adiponectin Measurement
Total plasma adiponectin concentration was measured at
baseline and at the six-month follow-up in 473 participants who
had one or both plasma samples available using 4.5 hour solid-
phase ELISA kits (QuantikineH, Human Total Adiponectin/
Acrp30 Immunoassay, R&D systems, Abingdon, OX14 3NB,
UK); the detailed protocol accompanying the kits was followed
(http://www.rndsystems.com/pdf/drp300.pdf ). The intra- and
inter-assay coefficients of variation were 3.4% and 8.2%.
Characteristics of participants with and without adiponectin
measurements available did not differ (data not shown).
Statistical Methods
For the analyses of the randomized groups, all trial participants
for whom plasma adiponectin measurements were available at the
baseline or follow-up visits were assigned to their randomized
treatment group, irrespective of compliance. Plasma adiponectin
levels were right-skewed and log-transformed for the analyses. The
effect of Se supplementation was estimated by using linear mixed
models on log-transformed adiponectin levels with fixed treat-
ment-by-time interactions and random between-subject variations
in both baseline adiponectin levels (intercepts) and adiponectin
changes over time (slopes) in 473 participants with at least one
adiponectin measurement available either at baseline or at six




data Overall Placebo 100 200 300
P
value{
Participants 473 (100.0) 112 (23.7) 120 (25.4) 124 (26.2) 117 (24.7)
Study center 473 0.99
Bungay (eastern England) 117 (24.7) 29 (25.9) 29 (24.2) 31 (25.0) 28 (23.9)
Guisborough (northeast England) 187 (39.5) 44 (39.3) 49 (40.8) 48 (38.7) 46 (39.3)
Bromsgrove (central England) 112 (23.7) 25 (22.3) 28 (23.3) 31 (25.0) 28 (23.9)
Linthorpe (northeast England) 57 (12.1) 14 (12.5) 14 (11.7) 14 (11.3) 15 (12.8)
Age (years) 471 67.5 (4.1) 67.6 (4.2) 67.3 (4.1) 67.3 (4.0) 67.7 (4.1) 0.82
Sex 473 0.88
Men 249 (52.6) 58 (51.8) 60 (50.0) 68 (54.8) 63 (53.8)
Women 224 (47.4) 54 (48.2) 60 (50.0) 56 (45.2) 54 (46.2)
Smoking status 473 0.70
Never 206 (43.6) 53 (47.3) 55 (45.8) 54 (43.5) 44 (37.6)
Former 222 (46.9) 51 (45.5) 53 (44.2) 56 (45.2) 62 (53.0)
Current 45 (9.5) 8 (7.1) 12 (10.0) 14 (11.3) 11 (9.4)
Drinking habits 473 0.54
Never 28 (5.9) 6 (5.4) 8 (6.7) 6 (4.8) 8 (6.8)
Former 34 (7.2) 6 (5.4) 6 (5.0) 14 (11.3) 8 (6.8)
Current 411 (86.9) 100 (89.3) 106 (88.3) 104 (83.9) 101 (86.3)
Body mass index (kg/m2) 471 27.5 (5.0) 27.4 (4.2) 27.8 (4.3) 27.4 (4.5) 27.6 (6.6) 0.91
Waist circumference (cm) 471 96.2 (13.8) 95.8 (13.3) 96.4 (14.7) 96.2 (12.4) 96.3 (14.9) 0.99
Total cholesterol level (mmol/L) 439 5.98 (1.07) 6.00 (1.03) 6.11 (1.18) 5.98 (1.03) 5.84 (1.01) 0.30
HDL cholesterol level (mmol/L) 439 1.61 (0.37) 1.65 (0.42) 1.59 (0.33) 1.59 (0.32) 1.63 (0.41) 0.59
Use of lipid-lowering medication 473 24 (5.1) 9 (8.0) 4 (3.3) 3 (2.4) 8 (6.8) 0.15
Use of diabetes medication 473 17 (3.6) 5 (4.5) 3 (2.5) 4 (3.2) 5 (4.3) 0.83
Plasma selenium level (ng/g) 451 88.5 (19.1) 88.3 (19.0) 87.3 (17.9) 88.1 (19.7) 90.2 (19.6) 0.72
Plasma adiponectin level (mg/mL) 431
Arithmetic mean (SD) 9.50 (5.07) 9.64 (5.05) 8.85 (4.54) 8.98 (4.86) 10.56 (5.66) 0.05
Geometric mean 8.07 8.26 7.51 7.69 8.92 0.16
Median (25th to 75th percentiles) 8.55 8.59 8.36 7.34 9.76
(5.74 to 12.70) (5.99 to 13.15) (5.66 to 10.54) (5.21 to 12.70) (6.12 to 14.78)
*Data are means (SDs) or numbers (%) in participants with at least one adiponectin measurement available either at baseline or at six months.
{P values for homogeneity of means or proportions across the four treatment groups, as obtained from one-way analysis-of-variance F tests for continuous variables
and Pearson’s chi-squared tests for categorical variables.
HDL, high-density lipoprotein.
doi:10.1371/journal.pone.0045269.t001
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Figure 1. CONSORT flow diagram.
doi:10.1371/journal.pone.0045269.g001
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months. Models were adjusted for sex and study center. Reverting
model results to the original scale, we estimated the ratio of
geometric mean adiponectin concentrations at six months to those
at baseline for each treatment group, as well as the sex- and center-
adjusted relative ratios of adiponectin change for the three active
treatment groups compared to placebo (treatment effect). For the
average sample size available per treatment group and an
uncorrected two-sided alpha level of 0.05, the power of the study
to detect an underlying 20% change in geometric mean
adiponectin concentrations comparing any Se supplementation
group to placebo was 77.1%.
In sensitivity analyses restricted to 340 participants with
adiponectin measurements available both at baseline and at six
months, standard analysis of covariance models relating log-
transformed adiponectin concentrations at six months to treatment
assignment adjusting for log-transformed adiponectin levels at
baseline, sex, and study center yielded similar results (data not
shown). To evaluate differential treatment effects by sex, all two-
and three-way interactions among time, treatment group, and sex
were included as fixed effects in the above mixed model. P-values
for treatment-by-sex interactions were obtained from Wald tests
for the joint null hypothesis that all three-way interaction
coefficients were simultaneously zero.
In addition to estimating Se supplementation efficacy from the
trial intervention results, we evaluated the cross-sectional associ-
ation between plasma Se concentrations and adiponectin levels at
baseline. Using linear regression models on log-transformed
adiponectin levels, we estimated the multivariable-adjusted geo-
metric mean ratios in baseline adiponectin levels for a 50-ng/g
increase in baseline Se levels, as well as for the three highest
quartiles of baseline Se compared with the lowest quartile. Tests
for linear trend across quartiles were conducted by including in
linear regression models an ordinal variable with the median
baseline Se level of each quartile. We used three models with
progressive degrees of adjustment. Model 1 adjusted for age, sex,
and study center; model 2 further adjusted for smoking, drinking,
body mass index, and waist circumference; and model 3 further
adjusted for total cholesterol, HDL cholesterol, lipid-lowering and
diabetes medications. Differences in baseline association by sex
were evaluated using interaction terms between baseline Se and
sex.
The reported P values were two-sided and not adjusted for
multiple testing. Statistical analyses were performed with Stata,
version 12 (StataCorp, College Station, Texas).
Results
Baseline Characteristics
Overall mean (SD) plasma Se at baseline was 88.5 (19.1) ng/g
[equivalent to 90.8 (19.6) mg/L] [35]. Baseline adiponectin levels
displayed high variability within the population [mean (SD) 9.50
(5.07) mg/mL]. There were no statistically significant differences
between treatment groups at baseline in plasma Se concentrations
(P = 0.72) or in other participant characteristics (Table 1).
Cross-sectional Association between Plasma Selenium
and Adiponectin Concentrations
At baseline, the geometric means of plasma adiponectin for
quartiles 1 through 4 of plasma Se were 8.30, 8.14, 7.71, and
7.79 mg/mL, respectively (Table 2). In models adjusted for age,
sex, and study center, the geometric mean of plasma adiponectin
was 7% lower (95% CI, 21% lower to 9% higher) in the highest
compared to the lowest quartile of plasma Se (P for linear trend
= 0.36). In fully adjusted models, the geometric mean of plasma
adiponectin was 14% lower (95% CI, 0 to 27%) in the highest than
in the lowest quartile of plasma Se (P for linear trend = 0.04).
Lipid levels (and particularly HDL cholesterol) were the main
covariates responsible for increasing the strength of the association
between the basic and fully adjusted models. The inverse
association between Se and adiponectin observed at baseline was
evident in men and women (P for interaction between Se and sex
= 0.93; Table S1).
Analysis of Randomized Groups
Ninety-four percent of the 473 participants missed less than
10% of the total number of study tablets according to pill count.
After six months of supplementation, plasma Se had increased
significantly and proportionally to the assigned dose in the three
active treatment groups but was unchanged in the placebo group.
Adiponectin levels, however, remained virtually unchanged after
six months of intervention in the four treatment groups (Table 3).
Adjusting for longitudinal changes in the placebo group, geometric
mean adiponectin levels decreased by 4% (95% CI, 18% lower to
13% higher) after six months of Se supplementation at 100 mg/d,
decreased by 1% (95% CI, 15% lower to 16% higher) after
supplementation at 200 mg/d, and remained unchanged (95% CI,
15% lower to 18% higher) after supplementation at 300 mg/d
(overall P for the three active treatment groups compared to
placebo = 0.96).
The null effect of Se supplementation on adiponectin levels did
not differ significantly by sex (P for treatment-by-sex interaction
= 0.39; Table S2). In additional subgroup analyses, trial results
remained virtually unchanged after excluding 17 participants that
used diabetes medications at baseline (data not shown) and there
were no statistically significant differences across study centers, or
by category of body mass index, baseline plasma Se concentra-
tions, or baseline adiponectin concentrations (data not shown).
Adverse Events
No serious adverse events occurred. Twelve adverse events were
reported, which were principally stomach or abdominal discom-
fort. These were equally associated with Se or placebo and were
not dependent on dose (data not shown).
Discussion
To our knowledge this is the first randomized trial to examine
the effect of supplementation with Se as a single nutrient on a
biomarker of type-2 diabetes risk in a population of relatively low
Se status. In this study, we observed an inverse cross-sectional
association between plasma Se and adiponectin concentrations at
baseline, but Se supplementation for six months over a wide range
of doses had no effect on plasma adiponectin concentration. As
insulin resistance can be triggered by oxidative stress and
ameliorated by antioxidant treatment [36], we might have
expected some benefit of Se supplementation in our population
where Se status was rather low. In a population of similar Se status
to ours, higher baseline Se status did appear to protect against the
onset of hyperglycemia over a nine-year follow-up period, though
only among male participants [12]. In our study population, few
participants would have had maximized activities or concentra-
tions of selenoproteins; animal studies have shown that not only
excessive levels of GPx1 but also low levels of GPx1 and other
‘‘stress-related’’ selenoproteins can cause insulin resistance and
hyperglycaemia [37]. However, we found null effects of Se
supplementation not only overall, but also in subgroups defined by
gender, body mass index category, and baseline Se concentrations.
In a small trial in pigs, which are a good model for human
Selenium Supplementation and Adiponectin
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Table 2. Cross-sectional association between plasma selenium and adiponectin concentrations at baseline*














Participants (n) 419 106 106 105 102
Median baseline selenium level (ng/g) 88.0 66.9 81.2 92.9 109.0
Baseline adiponectin level (mg/mL)
Geometric mean (SD) 7.99 (1.86) 8.30 (1.73) 8.14 (1.81) 7.71 (1.76) 7.79 (2.13)
Geometric mean ratio (95% CI)
Model 1{ 1.00 1 1.03 1.02 0.93 0.36
(0.86 to 1.17) (Reference) (0.88 to 1.21) (0.88 to 1.20) (0.79 to 1.09)
Model 2{ 0.99 1 1.01 1.01 0.91 0.28
(0.85 to 1.15) (Reference) (0.86 to 1.18) (0.87 to 1.19) (0.78 to 1.07)
Model 31 0.90 1 1.00 0.95 0.86 0.04
(0.78 to 1.04) (Reference) (0.86 to 1.16) (0.82 to 1.10) (0.73 to 1.00)
*Results were obtained from linear regression models of log-transformed adiponectin levels on selenium levels using only cross-sectional data from the
baseline visit.
{Model 1 adjusted for age (continuous), sex, and study center (Bungay, Guisborough, Bromsgrove, or Linthorpe).
{Model 2 further adjusted for smoking status (never, former, or current), drinking habits (never, former, or current), body mass index (continuous), and waist
circumference (continuous).
1Model 3 further adjusted for total cholesterol level (continuous), HDL cholesterol level (continuous), use of lipid lowering medications, and use of diabetes medications.
IP values for linear trend were obtained from Wald tests for the coefficient of an ordinal variable with the median baseline selenium level of each quartile in linear
regression models.
doi:10.1371/journal.pone.0045269.t002
Table 3. Effect of selenium supplementation on changes in plasma adiponectin and selenium concentrations after
six months*
Selenium dose (mg/d)
Variable Placebo 100 200 300 P value{
Plasma adiponectin level (mg/mL)
Geometric mean (SD) at baseline 8.26 (1.81) 7.51 (1.96) 7.69 (1.79) 8.92 (1.87)
Geometric mean (SD) at 6 mo 8.16 (1.96) 7.49 (2.19) 7.67 (1.82) 8.99 (1.78)
Ratio at 6 mo to baseline 1.01 0.97 1.00 1.01
(95% CI) (0.89 to 1.13) (0.87 to 1.08) (0.90 to 1.11) (0.89 to 1.13)
Relative ratio 1 0.96 0.99 1.00 0.96
(95% CI) (Reference) (0.82 to 1.13) (0.85 to 1.16) (0.85 to 1.18)
P value{ 0.66 0.92 0.99
Plasma selenium level (ng/g)
Arithmetic mean (SD) at baseline 88.3 (19.0) 87.3 (17.9) 88.1 (19.7) 90.2 (19.6)
Arithmetic mean (SD) at 6 mo 90.2 (26.8) 143.9 (25.9) 188.1 (42.9) 225.9 (52.4)
Change from baseline to 6 mo 2.1 57.8 100.3 136.4
(95% CI) (24.9 to 9.0) (51.0 to 64.6) (93.6 to 106.9) (129.2 to 143.6)
Difference in change 0 55.8 98.2 134.3 ,0.001
(95% CI) (Reference) (46.1 to 65.5) (88.6 to 107.8) (124.4 to 144.3)
P value{ ,0.001 ,0.001 ,0.001
*Results were obtained from linear mixed models on log-transformed adiponectin levels (and untransformed selenium levels) with fixed treatment-by-time interactions
and random between-subject variations in both baseline levels (intercepts) and longitudinal changes over time (slopes).
{P values comparing the ratio of geometric mean adiponectin levels (and the change in arithmetic mean selenium levels) at six months to baseline in each active
treatment group to placebo, as obtained from Wald tests for each treatment-by-time interaction coefficient in linear mixed models.
{Overall P value comparing the three active treatment groups to placebo, as obtained from the joint Wald test for all treatment-by-time interaction coefficients in linear
mixed models.
doi:10.1371/journal.pone.0045269.t003
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metabolism, no apparent increase in molecular markers of insulin
resistance was observed in adipose tissue after 16 weeks of dietary
supplementation with supranutritional Se [38].
It could be argued that our population was insufficiently obese
(BMI 27.5 kg/m2) for adiponectin levels to rise in response to Se
supplementation [39]. However, a number of studies have found
significantly lowered adiponectin levels in those with low or
normal overall fatness who have characteristics of the metabolic
syndrome such as insulin resistance [40,41].
Cross-sectional studies have previously found a positive
association between serum/plasma Se and type-2 diabetes or
fasting plasma glucose [8–11]. Furthermore, serum selenoprotein
P, a major component of Se in plasma, has been shown to be
negatively associated with serum adiponectin [5]. Our finding of a
negative association between plasma Se and adiponectin at
baseline accords with those results. The cross-sectional associations
between plasma Se, selenoprotein P and diabetes risk could be
explained by the linked expression of selenoprotein P and
gluconeogenic enzymes that promote the de novo biosynthesis of
glucose [3,7]. Thus significant correlations have been found
between serum selenoprotein P and adiponectin [5], fasting
plasma glucose [4] and HbA1c [4] while circulating selenoprotein
P concentration was significantly higher in people with type-2
diabetes or pre-diabetes than in those with normal glucose
tolerance [4–6]. This cross-sectional association, however, could
be driven by plasma glucose rather than by high Se; as an
example, the cultivation of hepatocytes in hyperglycaemic medium
significantly increased selenoprotein P secretion and mRNA levels
[3,4].
How do the results of our trial sit in the context of previous trial
findings? Participants in the NPC trial had a significantly increased
risk of type-2 diabetes on supplementation with 200 mg Se/d, the
effect being driven by those in the top Se tertile at baseline [13].
This may have resulted from an adverse effect of Se on insulin
signalling, acting through raised plasma selenoprotein P and
decreased inhibition of the phosphatase, PTP-1B, known to
antagonise insulin signalling [4,42,43]. At baseline, one third of the
participants in the NPC trial had plasma Se .121.6 mg/L (highest
tertile of the Se distribution) whereas that level was reached in only
5.8% of PRECISE participants. Our results are thus comparable
to those of participants in the lower tertiles of the NPC trial in
whom no significant effect was seen [13]; the adverse effects of
additional Se in some participants of both PRECISE and the NPC
trial may have been balanced by the achievement of an adequate
level of GPx1 and other ‘‘stress-related’’ selenoproteins in others
[37].
As in PRECISE, Se supplementation had no effect on the risk of
type-2 diabetes in SELECT (RR 1.07, 99% CI 0.94–1.22 [14];
RR 1.04, 99% CI 0.91–1.18 [15]). This similarity is at first
surprising as SELECT participants had a much higher baseline Se
status than those in PRECISE and even than those in the top
tertile of the NPC trial (mean/median serum/plasma Se, 136 vs 91
and 122 mg/L, respectively) [13,14]. In SELECT, unlike PRE-
CISE or indeed the top tertile of NPC, the expression or
concentration of selenoprotein P may already have reached a
plateau [44] or passed a threshold of risk prior to supplementation
in almost all participants. Thus if an increase in selenoprotein P
concentration is the cause of increased type-2 diabetes risk as
suggested by some authors [4–7], no adverse effect of additional Se
would have been seen, as was indeed the case. The existence of a
U-shaped association between selenoprotein activity/concentra-
tion and type-2 diabetes risk might explain some of the apparently
contradictory findings [45].
Another possible reason for a lack of effect of Se supplemen-
tation on adiponectin (PRECISE) or type-2 diabetes (SELECT) is
that Se or selenoprotein P does not cause an increased risk of type-
2 diabetes or a fall in circulating adiponectin. To date, apart from
the findings in the top tertile of the NPC trial, which derive from a
post-hoc analysis of a small trial, all the evidence linking Se or
selenoprotein P to type-2 diabetes is cross-sectional. The
conflicting observations that selenoprotein P knock-out mice had
higher blood adiponectin levels than wild-type mice [5], and that
knock-down of selenoprotein P in adipocytes markedly lowered the
expression of adiponectin [27], do not fit with a causal
relationship, nor can such a relationship explain the opposite
effects of selenoprotein P and adiponectin on AMPK, a positive
regulator of insulin synthesis [4,22]. Although Misu and colleagues
found a correlation between selenoprotein P and circulating
adiponectin in 36 type-2 diabetics, it was not strong, explaining
only 13% of the variance in adiponectin concentration [5].
Furthermore, they found no relationship between selenoprotein P
and QUICKI (quantitative insulin sensitivity index), a marker of
insulin resistance [5]. Evidence from two small interventions also
fails to support a diabetogenic effect of Se; one study found no
significant disturbances in plasma glucose after six weeks of
supplementation with 150 mg/d Se as dairy- or yeast-Se [46] while
the other, a randomized, controlled trial, found that 200 mg Se/d
as yeast-Se for six weeks significantly lowered fasting serum insulin
and HOMA-IR (homeostasis model assessment of insulin resis-
tance) [47].
A major limitation of our study was the high variability of
plasma adiponectin concentrations. In spite of this, we found a
significant association between Se and adiponectin levels at
baseline and the power of our analysis of randomized treatment
groups to detect an underlying difference of 20% in geometric
mean adiponectin concentrations between the Se supplementation
groups and placebo was 77.1%. Follow-up was only for six months
which may not have been long enough to see an effect. However,
adiponectin can increase significantly within weeks in response to
treatment with PPAR-c ligands such as the thiazolidinediones,
even in lean subjects [48]. As Se supplementation has been shown
to increase the synthesis of a PPAR-gamma activator [24], Se-
supplementation might have had a fairly rapid effect by that
mechanism. Lastly, the age-range of the participants was restricted
(60–74y), and our findings may not apply to younger age groups.
In summary, we found an inverse association of Se and
adiponectin concentrations at baseline but no effect of supple-
mentation for six months with 100, 200 or 300 mg/d of Se as Se-
yeast on plasma adiponectin concentrations. Given the positive
cross-sectional associations seen between biomarkers of Se and
type-2 diabetes and the adverse effect seen in the NPC trial in a
US population, our results are reassuring, at least for populations
of equivalent Se status to ours i.e. those of other European
countries. However, as we measured plasma adiponectin as a
biomarker and not glucose or insulin and our trial only lasted for
six months, additional research is needed to characterize fully the
role of Se in diabetes risk.
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